|
(1)Hartmann, J. T., and Bokemeyer, C. (1999) Chemotherapy for renal cell carcinoma. Anticancer Res 19, 1541-3.
(2)Chow, W. H., Devesa, S. S., Warren, J. L., and Fraumeni, J. F., Jr. (1999) Rising incidence of renal cell cancer in the United States. Jama 281, 1628-31.
(3)Bukowski, R. M. (2000) Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma. Semin Oncol 27, 204-12.
(4)Fischetti, G., Cuzari, S., Leone, P., De Martino, P., Musy, M., Mariani, S., Fraioli, A., and Valentini, M. A. (2002) [Immunotherapy in the management of metastatic renal carcinoma]. Minerva Urol Nefrol 54, 113-7.
(5)Fossa, S. D. (2000) Interferon in metastatic renal cell carcinoma. Semin Oncol 27, 187-93.
(6)Margolin, K. A. (2000) Interleukin-2 in the treatment of renal cancer. Semin Oncol 27, 194-203.
(7)Robson, C. J., Churchill, B. M., and Anderson, W. (1969) The results of radical nephrectomy for renal cell carcinoma. J Urol 101, 297-301.
(8)Khoury, S. (1982) The treatment of metastasis from renal cell carcinoma. Prog Clin Biol Res 100, 541-7.
(9)Kinouchi, T., and Kotake, T. (1994) [Management of advanced renal cell carcinoma: surgical treatment of metastasis]. Hinyokika Kiyo 40, 919-24.
(10)Storkel, S., Eble, J. N., Adlakha, K., Amin, M., Blute, M. L., Bostwick, D. G., Darson, M., Delahunt, B., and Iczkowski, K. (1997) Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80, 987-9.
(11)Sufrin, G., Chasan, S., Golio, A., and Murphy, G. P. (1989) Paraneoplastic and serologic syndromes of renal adenocarcinoma. Semin Urol 7, 158-71.
(12)Nseyo, U. O., Williams, P. D., and Murphy, G. P. (1986) Clinical significance of erythropoietin levels in renal carcinoma. Urology 28, 301-6.
(13)Sufrin, G., Mink, I., Fitzpatrick, J., Moore, R., and Murphy, G. P. (1978) Coagulation factors in renal adenocarcinoma. J Urol 119, 727-30.
(14)Echenique, J. E., and Graham, S. D., Jr. (1988) Significance of lipid-associated sialic acid and CA 19-9 as tumor markers for renal cell carcinoma. Urology 32, 397-400.
(15)Babaian, R. J., and Swanson, D. A. (1982) Serum haptoglobin: a nonspecific tumor marker for renal cell carcinoma. South Med J 75, 1345-8.
(16)Chu, T. M., Shukla, S. K., Mittleman, A. O., and Murphy, G. P. (1974) Plasma carcinoembryonic antigen in renal cell carcinoma patients. J Urol 111, 742-4.
(17)Bugert, P., and Kovacs, G. (1996) Molecular differential diagnosis of renal cell carcinomas by microsatellite analysis. Am J Pathol 149, 2081-8.
(18)Motzer, R. J., Bacik, J., Mariani, T., Russo, P., Mazumdar, M., and Reuter, V. (2002) Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20, 2376-81.
(19)Hedenfalk, I., Duggan, D., Chen, Y., Radmacher, M., Bittner, M., Simon, R., Meltzer, P., Gusterson, B., Esteller, M., Kallioniemi, O. P., Wilfond, B., Borg, A., and Trent, J. (2001) Gene-expression profiles in hereditary breast cancer. N Engl J Med 344, 539-48.
(20)Ono, K., Tanaka, T., Tsunoda, T., Kitahara, O., Kihara, C., Okamoto, A., Ochiai, K., Takagi, T., and Nakamura, Y. (2000) Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 60, 5007-11.
(21)Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., Bloomfield, C. D., and Lander, E. S. (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531-7.
(22)Okabe, H., Satoh, S., Kato, T., Kitahara, O., Yanagawa, R., Yamaoka, Y., Tsunoda, T., Furukawa, Y., and Nakamura, Y. (2001) Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 61, 2129-37.
(23)Young, A. N., Amin, M. B., Moreno, C. S., Lim, S. D., Cohen, C., Petros, J. A., Marshall, F. F., and Neish, A. S. (2001) Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol 158, 1639-51.
(24)Boer, J. M., Huber, W. K., Sultmann, H., Wilmer, F., von Heydebreck, A., Haas, S., Korn, B., Gunawan, B., Vente, A., Fuzesi, L., Vingron, M., and Poustka, A. (2001) Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array. Genome Res 11, 1861-70.
(25)Takahashi, M., Rhodes, D. R., Furge, K. A., Kanayama, H., Kagawa, S., Haab, B. B., and Teh, B. T. (2001) Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci U S A 98, 9754-9.
(26)Kurth, I., Willimann, K., Schaerli, P., Hunziker, T., Clark-Lewis, I., and Moser, B. (2001) Monocyte selectivity and tissue localization suggests a role for breast and kidney-expressed chemokine (BRAK) in macrophage development. J Exp Med 194, 855-61.
(27)Van Coillie, E., Van Damme, J., and Opdenakker, G. (1999) The MCP/eotaxin subfamily of CC chemokines. Cytokine Growth Factor Rev 10, 61-86.
(28)Mackay, C. R. (2001) Chemokines: immunology''s high impact factors. Nat Immunol 2, 95-101.
(29)Balkwill, F. (2003) Chemokine biology in cancer. Semin Immunol 15, 49-55.
(30)Coussens, L. M., and Werb, Z. (2001) Inflammatory cells and cancer: think different! J Exp Med 193, F23-6.
(31)Gordon, L. (2001) Inflammatory breast cancer. Clin J Oncol Nurs 5, 175-6.
(32)Struyf, S., Schutyser, E., Gouwy, M., Gijsbers, K., Proost, P., Benoit, Y., Opdenakker, G., Van Damme, J., and Laureys, G. (2003) PARC/CCL18 is a plasma CC chemokine with increased levels in childhood acute lymphoblastic leukemia. Am J Pathol 163, 2065-75.
(33)Scotton, C. J., Wilson, J. L., Scott, K., Stamp, G., Wilbanks, G. D., Fricker, S., Bridger, G., and Balkwill, F. R. (2002) Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 62, 5930-8.
(34)Bachelder, R. E., Wendt, M. A., and Mercurio, A. M. (2002) Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 62, 7203-6.
(35)Hall, J. M., and Korach, K. S. (2003) Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol Endocrinol 17, 792-803.
(36)Helbig, G., Christopherson, K. W., 2nd, Bhat-Nakshatri, P., Kumar, S., Kishimoto, H., Miller, K. D., Broxmeyer, H. E., and Nakshatri, H. (2003) NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 278, 21631-8.
(37)Schioppa, T., Uranchimeg, B., Saccani, A., Biswas, S. K., Doni, A., Rapisarda, A., Bernasconi, S., Saccani, S., Nebuloni, M., Vago, L., Mantovani, A., Melillo, G., and Sica, A. (2003) Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 198, 1391-402.
(38)Staller, P., Sulitkova, J., Lisztwan, J., Moch, H., Oakeley, E. J., and Krek, W. (2003) Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425, 307-11.
(39)Hromas, R., Broxmeyer, H. E., Kim, C., Nakshatri, H., Christopherson, K., 2nd, Azam, M., and Hou, Y. H. (1999) Cloning of BRAK, a novel divergent CXC chemokine preferentially expressed in normal versus malignant cells. Biochem Biophys Res Commun 255, 703-6.
(40)Frederick, M. J., Henderson, Y., Xu, X., Deavers, M. T., Sahin, A. A., Wu, H., Lewis, D. E., El-Naggar, A. K., and Clayman, G. L. (2000) In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. Am J Pathol 156, 1937-50.
(41)Etienne-Manneville, S., and Hall, A. (2002) Rho GTPases in cell biology. Nature 420, 629-35.
(42)Schmidt, A., and Hall, A. (2002) Guanine nucleotide exchange factors for Rho GTPases: turning on the switch. Genes Dev 16, 1587-609.
(43)Jaffe, A. B., and Hall, A. (2002) Rho GTPases in transformation and metastasis. Adv Cancer Res 84, 57-80.
(44)Daub, H., Gevaert, K., Vandekerckhove, J., Sobel, A., and Hall, A. (2001) Rac/Cdc42 and p65PAK regulate the microtubule-destabilizing protein stathmin through phosphorylation at serine 16. J Biol Chem 276, 1677-80.
(45)Etienne-Manneville, S., and Hall, A. (2001) Integrin-mediated activation of Cdc42 controls cell polarity in migrating astrocytes through PKCzeta. Cell 106, 489-98.
(46)Fritz, G., Just, I., and Kaina, B. (1999) Rho GTPases are over-expressed in human tumors. Int J Cancer 81, 682-7.
(47)Kamai, T., Arai, K., Tsujii, T., Honda, M., and Yoshida, K. (2001) Overexpression of RhoA mRNA is associated with advanced stage in testicular germ cell tumour. BJU Int 87, 227-31.
(48)Kleer, C. G., van Golen, K. L., Zhang, Y., Wu, Z. F., Rubin, M. A., and Merajver, S. D. (2002) Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. Am J Pathol 160, 579-84.
(49)Suwa, H., Ohshio, G., Imamura, T., Watanabe, G., Arii, S., Imamura, M., Narumiya, S., Hiai, H., and Fukumoto, M. (1998) Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br J Cancer 77, 147-52.
(50)Nobes, C. D., Lauritzen, I., Mattei, M. G., Paris, S., Hall, A., and Chardin, P. (1998) A new member of the Rho family, Rnd1, promotes disassembly of actin filament structures and loss of cell adhesion. J Cell Biol 141, 187-97.
(51)Hansen, S. H., Zegers, M. M., Woodrow, M., Rodriguez-Viciana, P., Chardin, P., Mostov, K. E., and McMahon, M. (2000) Induced expression of Rnd3 is associated with transformation of polarized epithelial cells by the Raf-MEK-extracellular signal-regulated kinase pathway. Mol Cell Biol 20, 9364-75.
(52)Zondag, G. C., Evers, E. E., ten Klooster, J. P., Janssen, L., van der Kammen, R. A., and Collard, J. G. (2000) Oncogenic Ras downregulates Rac activity, which leads to increased Rho activity and epithelial-mesenchymal transition. J Cell Biol 149, 775-82.
(53)Bhowmick, N. A., Ghiassi, M., Bakin, A., Aakre, M., Lundquist, C. A., Engel, M. E., Arteaga, C. L., and Moses, H. L. (2001) Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 12, 27-36.
(54)Sahai, E., Olson, M. F., and Marshall, C. J. (2001) Cross-talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility. Embo J 20, 755-66.
(55)Nobes, C. D., and Hall, A. (1995) Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 81, 53-62.
(56)Bishop, A. L., and Hall, A. (2000) Rho GTPases and their effector proteins. Biochem J 348 Pt 2, 241-55.
(57)Hall, A. (1998) Rho GTPases and the actin cytoskeleton. Science 279, 509-14.
(58)Turcotte, S., Desrosiers, R. R., and Beliveau, R. (2004) Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma. Am J Physiol Renal Physiol 286, F338-48.
(59)Turcotte, S., Desrosiers, R. R., and Beliveau, R. (2003) HIF-1alpha mRNA and protein upregulation involves Rho GTPase expression during hypoxia in renal cell carcinoma. J Cell Sci 116, 2247-60.
(60)Erin, E. M., Williams, T. J., Barnes, P. J., and Hansel, T. T. (2002) Eotaxin receptor (CCR3) antagonism in asthma and allergic disease. Curr Drug Targets Inflamm Allergy 1, 201-14.
(61)Bandeira-Melo, C., Herbst, A., and Weller, P. F. (2001) Eotaxins. Contributing to the diversity of eosinophil recruitment and activation. Am J Respir Cell Mol Biol 24, 653-7.
(62)Balkwill, F. (2004) Cancer and the chemokine network. Nat Rev Cancer 4, 540-50.
(63)Homey, B. (2004) Chemokines and chemokine receptors as targets in the therapy of psoriasis. Curr Drug Targets Inflamm Allergy 3, 169-74.
(64)Strieter, R. M., Belperio, J. A., Phillips, R. J., and Keane, M. P. (2004) Chemokines: angiogenesis and metastases in lung cancer. Novartis Found Symp 256, 173-84; discussion 184-8, 259-69.
(65)Rothenberg, M. E. (1999) Eotaxin. An essential mediator of eosinophil trafficking into mucosal tissues. Am J Respir Cell Mol Biol 21, 291-5.
(66)Nakanishi, H., Brewer, K. A., and Exton, J. H. (1993) Activation of the zeta isozyme of protein kinase C by phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 268, 13-6.
(67)Nakanishi, H., and Exton, J. H. (1992) Purification and characterization of the zeta isoform of protein kinase C from bovine kidney. J Biol Chem 267, 16347-54.
(68)Lozano, J., Berra, E., Municio, M. M., Diaz-Meco, M. T., Dominguez, I., Sanz, L., and Moscat, J. (1994) Protein kinase C zeta isoform is critical for kappa B-dependent promoter activation by sphingomyelinase. J Biol Chem 269, 19200-2.
(69)Bjorkoy, G., Overvatn, A., Diaz-Meco, M. T., Moscat, J., and Johansen, T. (1995) Evidence for a bifurcation of the mitogenic signaling pathway activated by Ras and phosphatidylcholine-hydrolyzing phospholipase C. J Biol Chem 270, 21299-306.
(70)Filomenko, R., Poirson-Bichat, F., Billerey, C., Belon, J. P., Garrido, C., Solary, E., and Bettaieb, A. (2002) Atypical protein kinase C zeta as a target for chemosensitization of tumor cells. Cancer Res 62, 1815-21.
(71)Kemp, S., Pujol, A., Waterham, H. R., van Geel, B. M., Boehm, C. D., Raymond, G. V., Cutting, G. R., Wanders, R. J., and Moser, H. W. (2001) ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations. Hum Mutat 18, 499-515.
(72)Burgess, D. L., Davis, C. F., Gefrides, L. A., and Noebels, J. L. (1999) Identification of three novel Ca(2+) channel gamma subunit genes reveals molecular diversification by tandem and chromosome duplication. Genome Res 9, 1204-13.
(73)Silver, D. L., Wang, N., and Vogel, S. (2003) Identification of small PDZK1-associated protein, DD96/MAP17, as a regulator of PDZK1 and plasma high density lipoprotein levels. J Biol Chem 278, 28528-32.
(74)Schwarze, S. R., Luo, J., Isaacs, W. B., and Jarrard, D. F. (2005) Modulation of CXCL14 (BRAK) expression in prostate cancer. Prostate.
(75)Arenberg, D. A., Keane, M. P., DiGiovine, B., Kunkel, S. L., Morris, S. B., Xue, Y. Y., Burdick, M. D., Glass, M. C., Iannettoni, M. D., and Strieter, R. M. (1998) Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J Clin Invest 102, 465-72.
(76)Arenberg, D. A., Polverini, P. J., Kunkel, S. L., Shanafelt, A., Hesselgesser, J., Horuk, R., and Strieter, R. M. (1997) The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer. J Leukoc Biol 62, 554-62.
(77)Belperio, J. A., Keane, M. P., Arenberg, D. A., Addison, C. L., Ehlert, J. E., Burdick, M. D., and Strieter, R. M. (2000) CXC chemokines in angiogenesis. J Leukoc Biol 68, 1-8.
(78)Keane, M. P., Arenberg, D. A., Lynch, J. P., 3rd, Whyte, R. I., Iannettoni, M. D., Burdick, M. D., Wilke, C. A., Morris, S. B., Glass, M. C., DiGiovine, B., Kunkel, S. L., and Strieter, R. M. (1997) The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 159, 1437-43.
(79)Vojtek, A. B., and Cooper, J. A. (1995) Rho family members: activators of MAP kinase cascades. Cell 82, 527-9.
(80)Shaulian, E., and Karin, M. (2001) AP-1 in cell proliferation and survival. Oncogene 20, 2390-400.
(81)Hill, C. S., Wynne, J., and Treisman, R. (1995) The Rho family GTPases RhoA, Rac1, and CDC42Hs regulate transcriptional activation by SRF. Cell 81, 1159-70.
(82)Welsh, C. F., Roovers, K., Villanueva, J., Liu, Y., Schwartz, M. A., and Assoian, R. K. (2001) Timing of cyclin D1 expression within G1 phase is controlled by Rho. Nat Cell Biol 3, 950-7.
(83)Sherr, C. J., and Roberts, J. M. (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13, 1501-12.
(84)Robles, A. I., Rodriguez-Puebla, M. L., Glick, A. B., Trempus, C., Hansen, L., Sicinski, P., Tennant, R. W., Weinberg, R. A., Yuspa, S. H., and Conti, C. J. (1998) Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo. Genes Dev 12, 2469-74.
(85)Kocher, O., Cheresh, P., Brown, L. F., and Lee, S. W. (1995) Identification of a novel gene, selectively up-regulated in human carcinomas, using the differential display technique. Clin Cancer Res 1, 1209-15.
(86)Datta, K., Li, J., Bhattacharya, R., Gasparian, L., Wang, E., and Mukhopadhyay, D. (2004) Protein kinase C zeta transactivates hypoxia-inducible factor alpha by promoting its association with p300 in renal cancer. Cancer Res 64, 456-62.
|